XFOR X4 Pharmaceuticals, Inc.
$3.50▲ +2.94%
Healthcare
Other
After hours
$3.50▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.25M
Avg Volume (10D) 863.6K
Key Metrics & Fundamentals
Market Cap
$347.01M
P/E Ratio
2.4
Div Yield
–%
52W Range
2.80 - 4.83
% vs 50 MA
-12.98%
% vs 200 MA
-11.09%
RSI-14
34.2
MACD Histogram
-0.0800
Beta (1Y vs SPY)
1.71
Free Cash Flow
-$25.79M
Gross Rev
$8.81M
Gross Profit
$7.19M
EBITDA
-$13.52M
COGS
$1.62M
Operating Exp
$23.58M
Operating Income
-$16.39M
EBIT
-$16.39M
Pretax Income
-$16.16M
Net Income
-$16.16M
EPS (Diluted)
-0.13
Price & Volume History
Loading chart…
Recent News
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · Sep 11, 2026 1:35 PM
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
GlobeNewswire · Sep 9, 2026 11:00 AM
X4 Pharmaceuticals Reaches FDA Agreement on Revised Phase 3 Trial for Chronic Neutropenia Treatment
MT Newswires · Sep 8, 2026 12:18 PM
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
GlobeNewswire · Sep 8, 2026 11:00 AM
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 1, 2026 8:30 PM
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
Zacks · Aug 11, 2026 4:00 PM
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 6, 2026 11:10 PM
X4 Pharmaceuticals: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 9:22 PM
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 6, 2026 8:15 PM
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates
Zacks · Aug 6, 2026 12:35 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See XFOR's money flow as a full page
Social Sentiment
No Reddit posts found for XFOR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.